Patent · US Active

Use of phospho-Akt as a biomarker of drug response

US10006078B2 · kind B2 · utility

1Cited by

1References

81Claims

0Family size

Assignee

Basilea Pharmaceutica AG · CH

Inventors

Heidi Lane · Biel-Benken, CH
Felix Bachmann · Basel, CH

Key dates

Filing date	Mar 28, 2012
Grant date	Jun 26, 2018
Priority date	—
Expiry date	Mar 28, 2032

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Use of phospho-Akt as a biomarker for predicting the response, such as resistance, to a compound, wherein phospho-Akt is Akt that has been phosphorylated on one or more residues, with the proviso that for Akt1, Akt2, and Akt3 the designation phospho-Akt is used to indicate phosphorylation at a site other than T308, T309 or T305 respectively, wherein the compound is a compound of general formula (I).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.